Cardiovascular disease (CVD) remains the major cause of morbidity and mortality worldwide. Accumulating evidence indicates that atherosclerosis and its sequelae, coronary artery disease, contribute to the majority of cardiovascular deaths. Atherosclerosis is a chronic inflammatory disease of the arteries in which atherosclerotic plaques form within the vessel wall. Epidemiological studies have identified various risk factors for atherosclerosis, such as diabetes, hyperlipidemia, smoking, genetic predisposition, and sedentary lifestyle.
Recent Advances:
Through the advancement of genetic manipulation techniques and their use in cardiovascular biology, it was shown that small RNAs, especially microRNAs (miRNAs), are dynamic regulators of disease pathogenesis. They are considered to be central during the regulation of gene expression through numerous mechanisms and provide a means to develop biomarkers and therapeutic tools for the diagnosis and therapy of atherosclerosis. Circulating miRNAs encapsulated within membrane-surrounded vesicles, which originate from diverse subcellular compartments, are now emerging as novel regulators of intercellular communication. The miRNAs, in both freely circulating and vesicle-bound forms, represent a valuable tool for diagnosing and monitoring CVD, recently termed as “liquid biopsy.”
Critical Issues:
However, despite the recent advancements in miRNA-based diagnostics and therapeutics, understanding how miRNAs can regulate atherosclerosis is still crucial to achieving an effective intervention and reducing the disease burden.
Future Directions:
We provide a landscape of the current developmental progression of RNA therapeutics as a holistic approach for treating CVD in different animal models and clinical trials. Future interrogations are warranted for the development of miRNA-based therapeutics to overcome challenges for the treatment of the disease.
Get full access to this article
View all access options for this article.
References
1.
AguirreA, MontserratN, ZacchignaS, NivetE, HishidaT, KrauseMN, KurianL, OcampoA, Vazquez-FerrerE, Rodriguez-EstebanC, and KumarS. In vivo activation of a conserved microRNA program induces mammalian heart regeneration. Cell Stem Cell, 15: 589–604, 2014.
2.
AharonA, TamariT, and BrennerB. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb Haemost, 100: 878–885, 2008.
3.
AnandS, MajetiBK, AcevedoLM, MurphyEA, MukthavaramR, ScheppkeL, HuangM, ShieldsDJ, LindquistJN, LapinskiPE, and KingPD. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med, 16: 909, 2010.
BellDA, HooperAJ, and BurnettJR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig drugs, 20: 265–272, 2011.
10.
BelleraN, BarbaI, Rodriguez-SinovasA, FerretE, AsínMA, Gonzalez-AlujasM, Pérez-RodonJ, EstevesM, FonsecaC, ToranN, and Garcia del BlancoB. Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling. J Am Heart Assoc, 3: e000946, 2014.
11.
BernardoBC, GaoXM, WinbanksCE, BoeyEJ, ThamYK, KiriazisH, GregorevicP, ObadS, KauppinenS, DuXJ, and LinRC. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A, 109: 17615–17620, 2012.
12.
BernsteinE, CaudyAA, HammondSM, and HannonGJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, 409: 363, 2001.
13.
BijkerkR, DuijsJM, RoetenMK, van Oeveren-RietdijkAM, BaeldeHJ, MongeM, VosJB, de BoerHC, and QuaxPH. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med, 13: 1577–1585, 2009.
14.
BlankenbergS, RupprechtHJ, BickelC, PeetzD, HafnerG, TiretL, MeyerJ, and AtheroGeneInvestigators. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation, 104: 1336–1342, 2001.
15.
BonauerA, CarmonaG, IwasakiM, MioneM, KoyanagiM, FischerA, BurchfieldJ, FoxH, DoebeleC, OhtaniK, and ChavakisE. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science, 324: 1710–1713, 2009.
16.
BoonRA and DimmelerS. MicroRNAs in myocardial infarction. Nat Rev Cardiol, 12: 135, 2015.
CastaldiA, ZagliaT, Di MauroV, CarulloP, ViggianiG, BorileG, Di StefanoB, SchiattarellaGG, GualazziMG, EliaL, and StirparoGG. MicroRNA-133 modulates the β1-adrenergic receptor transduction cascade. Circ Res, 115: 273–283, 2014.
26.
ChenP, PanJ, ZhangX, ShiZ, and YangX. The role of microRNA-181a in myocardial fibrosis following myocardial infarction in a rat model. Med Sci Monit, 24: 4121, 2018.
27.
ChenY and GorskiDH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 111: 1217–1226, 2008.
ChengY and ZhangC. MicroRNA-21 in cardiovascular disease. J Cardiovasc Transl Res, 3: 251–255, 2010.
30.
ChiavacciE, DolfiL, VerduciL, MeghiniF, GestriG, EvangelistaAMM, WilsonSW, CremisiF, and PittoL. MicroRNA 218 mediates the effects of Tbx5a over-expression on zebrafish heart development. PLoS One, 7: e50536, 2012.
31.
ChironiGN, BoulangerCM, SimonA, Dignat-GeorgeF, FreyssinetJM, and TedguiA. Endothelial microparticles in diseases. Cell Tissue Res, 335: 143, 2009.
32.
ChoeN, KwonJS, KimJR, EomGH, KimY, NamKI, AhnY, KeeHJ, and KookH. The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis, 229: 348–355, 2013.
33.
ChoiJL, LiS, and HanJY. Platelet function tests: a review of progresses in clinical application. BioMed Res Int, 2014: 456569, 2014.
34.
CirilloP, GolinoP, CalabroP, RagniM, ForteL, PiroO, De RosaS, PacileoM, and ChiarielloM. Activated platelets stimulate tissue factor expression in smooth muscle cells. Thromb Res, 112: 51–57, 2003.
35.
CondorelliG, LatronicoMV, and CavarrettaE. microRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol, 63: 2177–2187, 2014.
36.
CondorelliG, LatronicoMV, and DornGW. microRNAs in heart disease: putative novel therapeutic targets. Eur Heart J, 31: 649–658, 2010.
37.
CordesKR, SheehyNT, WhiteMP, BerryEC, MortonSU, MuthAN, LeeTH, MianoJM, IveyKN, and SrivastavaD. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature, 460: 705, 2009.
38.
CoumansFA, BrissonAR, BuzasEI, Dignat-GeorgeF, DreesEE, El-AndaloussiS, EmanueliC, GaseckaA, HendrixA, HillAF, and LacroixR. Methodological guidelines to study extracellular vesicles. Circ Res, 120: 1632–1648, 2017.
39.
d'AudigierC, CochainC, RossiE, GuérinCL, BiècheI, BlandinièresA, MarsacB, SilvestreJS, GaussemP, and SmadjaDM. Thrombin receptor PAR-1 activation on endothelial progenitor cells enhances chemotaxis-associated genes expression and leukocyte recruitment by a COX-2-dependent mechanism. Angiogenesis, 18: 347–359, 2015.
40.
Dangwal S and ThumT. microRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol, 54: 185–203, 2014
41.
DanielJM, PenzkoferD, TeskeR, DutzmannJ, KochA, BielenbergW, BonauerA, BoonRA, FischerA, BauersachsJ, and Van RooijE. Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovasc Res, 103: 564–572, 2014.
42.
De RosaS, CurcioA, and IndolfiC. Emerging role of microRNAs in cardiovascular diseases. Circ J, 78: 567–575, 2014.
43.
DentelliP and BrizziMF. Endothelial progenitor cells and their potential clinical implication in cardiovascular disorders. J Endocrinol Invest, 32: 370–382, 2009.
44.
DentelliP, RossoA, OrsoF, OlgasiC, TavernaD, and BrizziMF. microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol, 30: 1562–1568, 2010.
45.
DesjarlaisM, DussaultS, DhahriW, MathieuR, and RivardA. MicroRNA-150 modulates ischemia-induced neovascularization in atherosclerotic conditions. Arterioscler Thromb Vasc Biol, 37: 900–908, 2017.
46.
Dignat-GeorgeF and BoulangerCM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol, 31: 27–33, 2011.
47.
DoyleB and CapliceN. Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol, 49: 2073–2080, 2007.
48.
DuyguB, de WindtLJ, and da Costa MartinsPA. Targeting microRNAs in heart failure. Trends Cardiovasc Med, 26: 99–110, 2016.
49.
This reference has been deleted.
50.
EdingJE, DemkesCJ, LynchJM, SetoAG, MontgomeryRL, SemusHM, JacksonAL, IsabelleM, ChimentiS, and van RooijE. The efficacy of cardiac anti-miR-208a therapy is stress dependent. Mol Ther, 25: 694–704, 2017.
51.
EliaL, ContuR, QuintavalleM, VarroneF, ChimentiC, RussoMA, CiminoV, DeLM, FrustaciA, CatalucciD, and CondorelliG. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation, 120: 2377–2385, 2009.
52.
FangY, ShiC, ManduchiE, CivelekM, and DaviesPF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A, 107: 13450–13455, 2010.
53.
FaridaniOR, AbdullayevI, Hagemann-JensenM, SchellJP, LannerF, and SandbergR. Single-cell sequencing of the small-RNA transcriptome. Nat Biotechnol, 34: 1264, 2016.
54.
FasanaroP, D'AlessandraY, Di StefanoV, MelchionnaR, RomaniS, PompilioG, CapogrossiMC, and MartelliF. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem, 283: 15878–15883, 2008.
55.
FelicianG, CollesiC, LusicM, MartinelliV, FerroMD, ZentilinL, ZacchignaS, and GiaccaM. Epigenetic modification at Notch responsive promoters blunts efficacy of inducing notch pathway reactivation afteNF myocardial infarction. Circ Res, 115: 636–649, 2014.
56.
FengB and ChakrabartiS. miR-320 regulates glucose-induced gene expression in diabetes. ISRN Endocrinol, 2012: 549875, 2012.
57.
FichtlschererS, De RosaS, FoxH, SchwietzT, FischerA, LiebetrauC, WeberM, HammCW, RöxeT, Müller-ArdoganM, and BonauerA. Circulating microRNAs in patients with coronary artery disease. Circ Res, 107: 677–684, 2010.
58.
FishJE, SantoroMM, MortonSU, YuS, YehRF, WytheJD, IveyKN, BruneauBG, StainierDY, and SrivastavaD. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell, 15: 272–284, 2008.
59.
FreedmanJE, ErcanB, MorinKM, LiuCT, TamerL, AyazL, KanadasiM, CicekD, SeyhanAI, AkilliRE, and CamciC. The distribution of circulating microRNA and their relation to coronary disease. F1000Res, 1: 50, 2012.
60.
GaoW, HeHW, WangZM, ZhaoH, LianXQ, WangYS, ZhuJ, YanJJ, ZhangDG, YangZJ, and WangLS. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis, 11: 55, 2012.
61.
GhoshG, SubramanianIV, AdhikariN, ZhangX, JoshiHP, BasiD, ChandrashekharYS, HallJL, RoyS, ZengY, and RamakrishnanS. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-α isoforms and promotes angiogenesis. J Clin Invest, 120: 4141–4154, 2010.
62.
HahnC and SchwartzMA. Mechanotransduction in vascular physiology and atherogenesis. Nat Rev Mol Cell Biol, 10: 53, 2009.
63.
HalkeinJ, TabruynSP, Ricke-HochM, HaghikiaA, ScherrM, CastermansK, MalvauxL, LambertV, ThiryM, SliwaK, and NoelA. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest, 123: 2143–2154, 2013.
64.
HanssonGK and HermanssonA. The immune system in atherosclerosis. Nat Immunol, 12: 204, 2011.
65.
HarrisTA, YamakuchiM, FerlitoM, MendellJT, and LowensteinCJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A, 105: 1516–1521, 2008.
66.
HaverVG, SlartRH, ZeebregtsCJ, PeppelenboschMP, and TioRA. Rupture of vulnerable atherosclerotic plaques: microRNAs conducting the orchestra?. Trends Cardiovasc Med, 20: 65–71, 2010.
67.
HergenreiderE, HeydtS, TréguerK, BoettgerT, HorrevoetsAJ, ZeiherAM, SchefferMP, FrangakisAS, YinX, MayrM, and BraunT. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol, 14: 249, 2012.
68.
HinkelR, PenzkoferD, ZühlkeS, FischerA, HusadaW, XuQF, BalochE, van RooijE, ZeiherAM, KupattC, and DimmelerS. Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation, 128: 1066–1075, 2013.
69.
HuY, FoteinosG, XiaoQ, and XuQ. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apoE-deficient mice. Atherosclerosis, 199: 467, 2008.
70.
HuangRS, HuGQ, LinB, LinZY, and SunCC. MicroRNA-125 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J Investig Med, 58: 961–967, 2010.
71.
HullingerTG, MontgomeryRL, SetoAG, DickinsonBA, SemusHM, LynchJM, DalbyCM, RobinsonK, StackC, LatimerPA, and HareJM. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res, 110: 71–81, 2012.
72.
HulsmansM, SinnaeveP, Van der SchuerenB, MathieuC, JanssensS, and HolvoetP. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J Clin Endocrinol Metab, 97: E1213–E1218, 2012.
73.
HusainK, HernandezW, AnsariRA, and FerderL. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem, 6: 209, 2015.
74.
JansenF, NickenigG, and WernerN. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res, 120: 1649–1657, 2017.
75.
JansenF, StumpfT, ProebstingS, FranklinBS, WenzelD, PfeiferP, FlenderA, SchmitzT, YangX, FleischmannBK, and NickenigG. Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6. J Mol Cell Cardiol, 104: 43–52, 2017.
76.
JansenF, YangX, HoelscherM, CattelanA, SchmitzT, ProebstingS, WenzelD, VosenS, FranklinBS, FleischmannBK, and NickenigG, Endothelial microparticle-mediated transfer of microRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation, 128: 2026–2038, 2013.
77.
JansenF, YangX, HoyerFF, PaulK, HeiermannN, Ulrich BecherM, Abu HusseinN, KebschullM, BedorfJ, FranklinBS, LatzE, NickenigG, WernerN. Endothelial microparticle uptake in target cells is annexin I/phosphatidylserine receptor dependent and prevents apoptosis. Arterioscler Thromb Vasc Biol, 32: 1925–1935, 2012.
78.
JansenF, YangX, ProebstingS, HoelscherM, PrzybillaD, BaumannK, SchmitzT, DolfA, EndlE, FranklinBS, SinningJ-M, Vasa-NicoteraM, NickenigG, and WernerN. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc, 3: e001249, 2014.
79.
JansenF, ZietzerA, StumpfT, FlenderA, SchmitzT, NickenigG, and WernerN. Endothelial microparticle-promoted inhibition of vascular remodeling is abrogated under hyperglycaemic conditions. J Mol Cell Cardiol, 112: 91–94, 2017.
80.
JiaX, ZhengS, XieX, ZhangY, WangW, WangZ, ZhangY, WangJ, GaoM, and HouY. MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. PLoS One, 8: e85639, 2013.
81.
KantersE, PasparakisM, GijbelsMJ, VergouweMN, Partouns-HendriksI, FijnemanRJ, ClausenBE, FörsterI, KockxMM, RajewskyK, and KraalG. Inhibition of NF-κB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest, 112: 1176–1185, 2003.
82.
KapustinAN, ChatrouML, DrozdovI, ZhengY, DavidsonSM, SoongD, FurmanikM, SanchisP, De RosalesRTM, Alvarez-HernandezD, and ShroffR. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res, 116: 1312–1323, 2015.
83.
KarakikesI, ChaanineAH, KangS, MuketeBN, JeongD, ZhangS, HajjarRJ, and LebecheD. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc, 2: e000078, 2013.
84.
KoleR, KrainerAR, and AltmanS. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov, 11: 125–140, 2012.
85.
KuehbacherA, UrbichC, ZeiherAM, and DimmelerS. Role of Dicer and Drosha .for endothelial microRNA expression and angiogenesis. Circ Res, 101: 59–68, 2007.
86.
KumarswamyR, VolkmannI, and ThumT. Regulation and function of miRNA-21 in health and disease. RNA Biol, 8: 706–713, 2011.
87.
LeeY, AhnC, HanJ, ChoiH, KimJ, YimJ, LeeJ, ProvostP, RådmarkO, KimS, and KimVN. The nuclear RNase III Drosha initiates microRNA processing. Nature, 425: 415, 2003.
88.
LeeperNJ, RaiesdanaA, KojimaY, ChunHJ, AzumaJ, MaegdefesselL, KunduRK, QuertermousT, TsaoPS, and SpinJM. MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol, 226: 1035–1043, 2011.
89.
LevulaM, OksalaN, MennanderA, TarkkaM, KloppN, IlligT, KähönenM, KarhunenPJ, and LaaksonenR. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis, 219: 211–217, 2011.
90.
LiH, ZhaoJ, LiuB, LuoJ, LiZ, QinX, and WeiY. MicroRNA-320 targeting neuropilin 1 inhibits proliferation and migration of vascular smooth muscle cells and neointimal formation. Int J Med Sci, 16: 106, 2019.
91.
LiJ, ZhangY, LiuY, DaiX, LiW, CaiX, YinY, WangQ, XueY, WangC, and LiD. Microvesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem, 288: 23586–23596, 2013.
92.
LiL, ZhuD, HuangL, ZhangJ, BianZ, ChenX, LiuY, ZhangCY, and ZenK. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS One, 7: e46957, 2012.
93.
LiM, LiuQ, LeiJ, WangX, ChenX, and DingY. MiR-362-3p inhibits the proliferation and migration of vascular smooth muscle cells in atherosclerosis by targeting ADAMTS1. Biochem Biophys Res Commun, 493: 270–276, 2017.
LiY, YangC, ZhangL, and YangP. MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis. Cell Mol Biol Lett, 22: 3, 2017.
96.
LiangY, RidzonD, WongL, and ChenC. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics, 8: 166, 2007.
97.
LiaoYC, WangYS, GuoYC, LinWL, ChangMH, and JuoSHH. Let-7g improves multiple endothelial functions through targeting transforming growth factor-beta and SIRT-1 signaling. J Am Coll Cardiol, 63: 1685–1694, 2014.
98.
LibbyP, RidkerPM, and HanssonGK. Progress and challenges in translating the biology of atherosclerosis. Nature, 473: 317, 2011.
99.
LibbyP, RidkerPM, and MaseriA. Inflammation and atherosclerosis. Circulation, 105: 1135–1143, 2002.
100.
LinB, FengDG, WangF, WangJX, XuCG, ZhaoH, and ChengZY. MiR-365 participates in coronary atherosclerosis through regulating IL-6. Eur Rev Med Pharmacol Sci, 20: 5186–5192, 2016.
101.
LiuX, DongY, ChenS, ZhangG, ZhangM, GongY, and LiX. Circulating microRNA-146a and microRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction. Cardiology, 132: 233–241, 2015.
102.
This reference has been deleted.
103.
LiuY, LiQ, HosenMR, ZietzerA, FlenderA, LevermannP, SchmitzT, FrühwaldD, GoodyP, NickenigG, and WernerN. Atherosclerotic conditions promote the packaging of functional microRNA-92a-3p into endothelial microvesicles. Circ Res, 124: 575–587, 2019.
104.
LucasT, BonauerA, and DimmelerS. RNA therapeutics in cardiovascular disease. Circ Res, 123: 205–220, 2018.
105.
LucasT, SchäferF, MüllerP, EmingSA, HeckelA, and DimmelerS. Light-inducible antimiR-92a as a therapeutic strategy to promote skin repair in healing-impaired diabetic mice. Nat Commun, 8: 1–9, 2017.
106.
MaS, TianXY, ZhangY, MuC, ShenH, BismuthJ, PownallHJ, HuangY, and WongWT. E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis. Sci Rep, 6: 22910, 2016.
107.
MaegdefesselL, AzumaJ, TohR, DengA, MerkDR, RaiesdanaA, LeeperNJ, RaazU, SchoelmerichAM, McConnellMV, and DalmanRL. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med, 4: 122ra22, 2012.
108.
MagentaA, CencioniC, FasanaroP, ZaccagniniG, GrecoS, Sarra-FerrarisG, AntoniniA, MartelliF, and CapogrossiMC. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ, 18: 1628–1639, 2011.
109.
MalekAM, AlperSL, and IzumoS. Hemodynamic shear stress and its role in atherosclerosis. JAMA, 282: 2035–2042, 1999.
110.
MarcucciR, GrifoniE, and GiustiB. On-treatment platelet reactivity: state of the art and perspectives. Vasc Pharmacol, 77: 8–18, 2016.
111.
MargolisLM, LessardSJ, EzzyatY, FieldingRA, and RivasDA. Circulating MicroRNA are predictive of aging and acute adaptive response to resistance exercise in men. J Gerontol A Biomed Sci Med Sci, 72: 1319–1326, 2017.
112.
MauseSF and WeberC. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res, 107: 1047–1057, 2010.
113.
McArthurK, FengB, WuY, ChenS, and ChakrabartiS. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes, 60: 1314–1323, 2011.
114.
McCarthyCP, JanuzziJLJr., and GagginHK. Type 2 myocardial infarction—an evolving entity. Circ J, 82: 309–315, 2018.
115.
McLendonJM, JoshiSR, SparksJ, MatarM, FewellJG, AbeK, OkaM, McMurtryIF, and GerthofferWT. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. J Control Release, 210: 67–75, 2015.
116.
MenghiniR, StöhrR, and FedericiM. MicroRNAs in vascular aging and atherosclerosis. Ageing Res Rev, 17: 68–78, 2014.
117.
This reference has been deleted.
118.
MessinaA, LangletF, ChachlakiK, RoaJ, RasikaS, JouyN, GalletS, GaytanF, ParkashJ, Tena-SempereM, and GiacobiniP. A microRNA switch regulates the rise in hypothalamic GnRH production before puberty. Nat Neurosci, 19: 835, 2016.
119.
MooreKJ, SheedyFJ, and FisherEA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol, 13: 709–721, 2013.
120.
MorenoP and PêgoAP. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem, 2: 87, 2014.
121.
NiCW, QiuH, and JoH. MicroRNA-663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells. Am J Physiol Heart Circ Physiol, 300: H1762–H1769, 2011.
122.
NieuwlandR, Falcon-PerezJM, SoekmadjiC, BoilardE, CarterD, and BuzasEI. Essentials of extracellular vesicles: posters on basic and clinical aspects of extracellular vesicles. J Extracell Vesicles, 7: 1548234, 2018.
123.
OhtaniK and DimmelerS. Control of cardiovascular differentiation by microRNAs. Basic Res Cardiol, 106: 5–11, 2011.
124.
OhtaniK and DimmelerS. Epigenetic regulation of cardiovascular differentiation. Cardiovasc Res, 90: 404–412, 2011.
125.
PanY, LiangH, LiuH, LiD, ChenX, LiL, ZhangCY, and ZenK. Platelet-secreted microRNA-223 promotes endothelial cell apoptosis induced by advanced glycation end products via targeting the insulin-like growth factor 1 receptor. J Immunol, 192: 437–446, 2014.
126.
ParahulevaMS, LippsC, ParvizB, HölschermannH, SchiefferB, SchulzR, and EulerG. MicroRNA expression profile of human advanced coronary atherosclerotic plaques. Sci Rep, 8: 1–9, 2018.
127.
PorrelloER, MahmoudAI, SimpsonE, JohnsonBA, GrinsfelderD, CansecoD, MammenPP, RothermelBA, OlsonEN, and SadekHA. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. Proc Natl Acad Sci U S A, 110: 187–192, 2013.
128.
PotenteM, GerhardtH, and CarmelietP. Basic and therapeutic aspects of angiogenesis. Cell, 146: 873–887, 2011.
129.
QinB, ShuY, XiaoL, LuT, LinY, YangH, and LuZ. MicroRNA-150 targets ELK1 and modulates the apoptosis induced by ox-LDL in endothelial cells. Mol Cell Biochem, 429: 45–58, 2017.
130.
QinB, XiaoB, LiangD, XiaJ, LiY, and YangH. MicroRNAs expression in ox-LDL treated HUVECs: miR-365 modulates apoptosis and Bcl-2 expression. Biochem Biophys Res Commun, 410: 127–133, 2011.
131.
RaggiP, GenestJ, GilesJT, RaynerKJ, DwivediG, BeanlandsRS, and GuptaM. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis, 276: 98–108, 2018.
132.
RaitoharjuE, LyytikäinenLP, LevulaM, OksalaN, MennanderA, TarkkaM, KloppN, IlligT, KähönenM, KarhunenPJ, and LaaksonenR. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis, 219: 211–217, 2011.
133.
RaynerKJ, SheedyFJ, EsauCC, HussainFN, TemelRE, ParathathS, Van GilsJM, RaynerAJ, ChangAN, SuarezY, and Fernandez-HernandoC. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest, 121: 2921–2931, 2011.
134.
This reference has been deleted.
135.
RobinsonP, ChuangTD, SriramS, PiL, LuoXP, PetersenB, and SchultzG. MicroRNA signature in wound healing following excimer laser ablation: role of miR-133b on TGF-β, CTGF, collagen and smooth muscle actin synthesis in corneal fibroblast. Invest Ophthalmol Vis Sci, 54: 5223, 2013.
136.
RohdeJH, WeigandJE, SuessB, and DimmelerS. A universal aptamer chimera for the delivery of functional microRNA-126. Nucleic Acid Ther, 25: 141–151, 2015.
RoyS, KhannaS, HussainSRA, BiswasS, AzadA, RinkC, GnyawaliS, ShiloS, NuovoGJ, and SenCK. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res, 82: 21–29, 2009.
139.
RubinshteinR, KuvinJT, SofflerM, LennonRJ, LaviS, NelsonRE, PumperGM, LermanLO, and LermanA. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J, 31: 1142–1148, 2010.
140.
SchäferF, WagnerJ, KnauA, DimmelerS, and HeckelA. Regulating angiogenesis with light-inducible antimiRs. Angew Chem Int Ed, 52: 13558–13561, 2013.
141.
SchiroA, WilkinsonFL, WestonR, SmythJV, Serracino-InglottF, and AlexanderMY. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis, 234: 295–302, 2014.
142.
SchluepT, LickliterJ, HamiltonJ, LewisDL, LaiCL, LauJY, LocarniniSA, GishRG, and GivenBD. Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers. Clin Pharmacol Drug Dev, 6: 350–362, 2017.
143.
SchoberA, Nazari-JahantighM, WeiY, BidzhekovK, GremseF, GrommesJ, MegensRT, HeyllK, NoelsH, HristovM, and WangS. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med, 20: 368, 2014.
144.
ScolesDR, MeeraP, SchneiderMD, PaulS, DansithongW, FigueroaKP, HungG, RigoF, BennettCF, OtisTS, and PulstSM. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature, 544: 362–366, 2017.
145.
SenCK, GordilloGM, KhannaS, and RoyS. Micromanaging vascular biology: tiny microRNAs play big band. J Vasc Res, 46: 527–540, 2009.
146.
ShaoH, TanY, EtonD, YangZ, UbertiMG, LiS, SchulickA, and YuH. Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells, 26: 1376–1384, 2008.
147.
SmallEM and OlsonEN. Pervasive roles of microRNAs in cardiovascular biology. Nature, 469: 336, 2011.
148.
SmallEM, SutherlandLB, RajagopalanKN, WangS, and OlsonEN. MicroRNA-218 regulates vascular patterning by modulation of Slit-Robo signaling. Circ Res, 107: 1336–1344, 2010.
149.
SmildeTJ, van WissenS, AwollersheimH, TripMD, KasteleinJ, and StalenhoefAF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 357: 577–581, 2001.
150.
SteinEA, DufourR, GagneC, GaudetD, EastC, DonovanJM, ChinW, TribbleDL, and McGowanM. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation, 126: 2283–2292, 2012.
151.
SuárezY, Fernández-HernandoC, YuJ, GerberSA, HarrisonKD, PoberJS, Iruela-ArispeML, MerkenschlagerM, and SessaWC. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A, 105: 14082–14087, 2008.
152.
SuárezY, WangC, ManesTD, and PoberJS. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol, 184: 21–25, 2010.
SunSG, ZhengB, HanM, FangXM, LiHX, MiaoSB, SuM, HanY, ShiHJ, and WenJK. miR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation. EMBO Rep, 12: 56–62, 2011.
155.
SunX, HeS, WaraAKM, IcliB, ShvartzE, TesmenitskyY, BelkinN, LiD, BlackwellTS, SukhovaGK, and CroceK. Systemic delivery of microRNA-181b inhibits nuclear factor-κb activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res, 114: 32–40, 2014.
156.
TabasI. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol, 10: 36–46, 2010.
157.
TakahashiY, SatohM, MinamiY, TabuchiT, ItohT, and NakamuraM. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin–angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci, 119: 395–405, 2010.
ThumT, GrossC, FiedlerJ, FischerT, KisslerS, BussenM, GaluppoP, JustS, RottbauerW, FrantzS, and CastoldiM. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 456: 980, 2008.
160.
TijsenAJ, van der MadeI, van den HoogenhofMM, WijnenWJ, van DeelED, de GrootNE, AlekseevS, FluiterK, SchroenB, GoumansMJ, and van der VeldenJ. The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res, 104: 61–71, 2014.
UrbichC, KaluzaD, FrömelT, KnauA, BennewitzK, BoonRA, BonauerA, DoebeleC, BoeckelJN, HergenreiderE, and ZeiherAM. MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A. Blood, 119: 1607–1616, 2012.
163.
ValadiH, Ekströ mK, BossiosA, Sjö strandM, LeeJJ, and Lö tvallJO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 9: 654–659, 2007.
164.
Van RooijE, SutherlandLB, LiuN, WilliamsAH, McAnallyJ, GerardRD, RichardsonJA, and OlsonEN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A, 103: 18255–18260, 2006.
165.
Van SolingenC, SeghersL, BijkerkR, DuijsJM, RoetenMK, van Oeveren-RietdijkAM, BaeldeHJ, MongeM, VosJB, de BoerHC, and QuaxPH. Antagomir-mediated silencing of endothelial cell specific Schober impairs ischemia-induced angiogenesis. J Cell Mol Med, 13: 1577–1585, 2009.
166.
VeerlaS, LindgrenD, KvistA, FrigyesiA, StaafJ, PerssonH, LiedbergF, ChebilG, GudjonssonS, Borg Å, and MånssonW. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer, 124: 2236–2242, 2009.
167.
Villarroya-BeltriC, Gutiérrez-VázquezC, Sánchez-CaboF, Pérez-HernándezD, VázquezJ, Martin-CofrecesN, Martinez-HerreraDJ, Pascual-MontanoA, MittelbrunnM, and Sánchez-MadridF. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nat Commun, 4: 2980, 2013.
168.
WahlquistC, JeongD, Rojas-MuñozA, KhoC, LeeA, MitsuyamaS, van MilA, ParkWJ, SluijterJP, DoevendansPA, and HajjarRJ. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature, 508: 531, 2014.
169.
WangD, DeuseT, StubbendorffM, ChernogubovaE, ErbenRG, EkenSM, JinH, LiY, BuschA, HeegerCH, and BehnischB. Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol, 35: 1945–1953, 2015.
170.
WangGK, ZhuJQ, ZhangJT, LiQ, LiY, HeJ, QinYW, and JingQ. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J, 31: 659–666, 2010.
171.
WangM, LiW, ChangGQ, YeCS, OuJS, LiXX, LiuY, CheangTY, HuangXL, and WangSM. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol, 31: 2044–2053, 2011.
172.
WangS, AuroraAB, JohnsonBA, QiX, McAnallyJ, HillJA, RichardsonJA, Bassel-DubyR, and OlsonEN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell, 15: 261–271, 2008.
173.
WangXH, QianRZ, ZhangW, ChenSF, JinHM, and HuRM. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol, 36: 181–188, 2009.
174.
WeberC and NoelsH. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 17: 1410, 2011.
175.
WeberM, BakerMB, MooreJP, and SearlesCD. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res Commun, 393: 643–648, 2010.
176.
WismanPP, RoestM, AsselbergsFW, De GrootPG, MollFL, Van Der GraafY, and De BorstGJ. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost, 12: 736–747, 2014.
177.
WuW, LiX, ZuoG, PuJ, WuX, and ChenS. The role of angiogenesis in coronary artery disease: a double-edged sword: intraplaque angiogenesis in physiopathology and therapeutic angiogenesis for treatment. Curr Pharm Des, 24: 451–464, 2018.
178.
WuYY, ChenYL, JaoYC, HsiehIS, ChangKC, and HongTM. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenesis, 17: 247–260, 2014.
179.
WürdingerT, TannousBA, SaydamO, SkogJ, GrauS, SoutschekJ, WeisslederR, BreakefieldXO, and KrichevskyAM. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell, 14: 382–393, 2008.
180.
XiongXD, ChoM, CaiXP, ChengJ, JingX, CenJM, LiuX, YangXL, and SuhY. A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res, 761: 15–20, 2014.
181.
XuZ, XiaoSB, XuP, XieQ, CaoL, WangD, LuoR, ZhongY, ChenHC, and FangLR. miR-365, a novel negative regulator of interleukin-6 gene expression, is cooperatively regulated by Sp1 and NF-κB. J Biol Chem, 286: 21401–21412, 2011.
182.
YananW, YingyuX, AoZ, MingyangW, ZihanF, and JunpingZ. Exosomes: an emerging factor in atherosclerosis. Biomed Pharmacother, 115: 108951, 2019.
183.
YangB, LinH, XiaoJ, LuY, LuoX, LiB, ZhangY, XuC, BaiY, WangH, and ChenG. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med, 13: 486, 2007.
YatsuFM and FisherM. Atherosclerosis: current concepts on pathogenesis and interventional therapies. Ann Neurol, 26: 3–12, 1989.
186.
YuML, WangJF, WangGK, YouXH, ZhaoXX, JingQ, and QinYW. Vascular smooth muscle cell proliferation is influenced by let-7d microRNA and its interaction with KRAS. Circ J, 75: 703–709, 2011.
187.
YuX and LiZ. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis. Int J Mol Med, 34: 923–933, 2014.
188.
ZerneckeA, BidzhekovK, NoelsH, ShagdarsurenE, GanL, DeneckeB, HristovM, KöppelT, JahantighMN, LutgensE, and WangS. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal, 2: ra81, 2009.
189.
ZhangDX and GuttermanDD. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol, 292: H2023–H2031, 2007.
190.
ZhangX, ShaoS, GengH, YuY, WangC, LiuZ, YuC, JiangX, DengY, GaoL, and ZhaoJ. Expression profiles of six circulating microRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: a clinical study. J Clin Endocrinol Metab, 99: E766–E774, 2014.
191.
ZhangY, LiHH, YangR, YangBJ, and GaoZY. Association between circulating microRNA-208a and severity of coronary heart disease. Scand J Clin Lab Invest, 77: 379–384, 2017.
